REDWOOD CITY, Calif., Dec. 17, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). The addition will take effect as part of the annual re-ranking of the NASDAQ Biotechnology Index upon market open on Monday, December 22, 2014.
The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. These companies must meet eligibility requirements, including minimum market capitalization and average daily trading volume, among other criteria. The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology Index Fund (Nasdaq:IBB), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges. For more information about the NASDAQ Biotechnology Index visit www.nasdaq.com.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The company's New Drug Application (NDA) for its lead product candidate, Patiromer for Oral Suspension, is under review for the treatment of hyperkalemia, a potentially life-threatening condition defined as abnormally elevated levels of potassium in the blood. The NDA is supported by a two part pivotal Phase 3 trial that has been completed and the primary and secondary endpoints were met. Relypsa has global royalty-free commercialization rights to Patiromer for Oral Suspension, which has intellectual property protection in the U.S. until at least 2030. More information is available at www.relypsa.com.
CONTACT: Sylvia Wheeler V.P., Investor Relations and Corporate Affairs 650 421 9504 IR@relypsa.com